Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 17/20 | 0.50 |
| ▸ | MMP13 | P45452 | 14/20 | 0.50 |
| ▸ | MMP1 | P03956 | 12/20 | 0.50 |
| ▸ | MMP2 | P08253 | 5/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899009 | 0.79 | MMP13 (0.52) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL231737 | 0.78 | MMP1 (0.55) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL6809658 | 0.74 | MMP13 (0.50) | MMP9MMP13MMP1MMP2 | |
| SCHEMBL13898980 | 0.72 | MMP9 (0.70) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL8443684 | 0.72 | MMP1 (0.51) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL7000013 | 0.71 | MMP13 (0.52) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL8455467 | 0.71 | MMP9 (0.70) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL13899011 | 0.71 | LMNA (0.47) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL7923801 | 0.70 | MMP9 (0.77) | MMP9MMP13MMP1MMP2MMP8 | |
| SCHEMBL4618781 | 0.70 | MMP13 (0.55) | MMP9MMP13MMP1MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0935963-A2 | The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders | Pfizer Products Inc. (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0935963-A2 | The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders | Pfizer Products Inc. (US) | 1999-08-18 | — | — | EP | disclosed |